CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Subjects With Advanced Solid Tumors Associated With Nectin-4 Expression

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05234606
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:42.464306+00:00
Published At: 2022-04-12T00:00:00+00:00
Record Updated At: 2022-04-12
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Urothelial Carcinoma", "Triple Negative Breast Cancer", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of Head and Neck", "Hormone Receptor-positive/HER2-negative Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-04-12"
protocolSection.identificationModule.nctId: "NCT05234606"
protocolSection.identificationModule.officialTitle: "A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Subjects With Advanced Solid Tumors Associated With Nectin-4 Expression"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.